Tarsus to Participate in Upcoming Investor Conferences
Tarsus (NASDAQ:TARS) announced that management will attend two investor events: the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, and the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tarsus (NASDAQ:TARS) announced that management will attend two investor events: the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, and the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, which will include a fireside chat at 6:00 a.m. PT / 9:00 a.m. ET. Live webcasts, replays, and additional details will be available in the events section of the Tarsus website, with replays posted within 48 hours and archived for a limited time.
Details
News Market Reaction – TARS
On Sep 2, the first trading day after this news, TARS closed 11.80% above the previous close. Argus tracked a peak move of +21.9% during that session. Our momentum scanner recorded 78 alerts for this stock that day. Relative volume reached 3.4x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:
- Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th
- H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15th, where management plans to participate in a fireside chat at 6:00 a.m. PT / 9:00 a.m. ET.
Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution)
Media Contact:
Adrienne Kemp
Vice President, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.